Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 10,000 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $49.87, for a total transaction of $498,700.00. Following the completion of the transaction, the insider now owns 95,648 shares of the company's stock, valued at $4,769,965.76. This represents a 9.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Catriona Yale also recently made the following trade(s):
- On Monday, December 16th, Catriona Yale sold 9,074 shares of Akero Therapeutics stock. The shares were sold at an average price of $29.11, for a total transaction of $264,144.14.
Akero Therapeutics Price Performance
AKRO opened at $51.84 on Friday. The company's 50 day simple moving average is $37.02 and its 200 day simple moving average is $31.68. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. Akero Therapeutics, Inc. has a 1 year low of $17.86 and a 1 year high of $58.40. The stock has a market capitalization of $3.62 billion, a PE ratio of -13.82 and a beta of -0.11.
Institutional Investors Weigh In On Akero Therapeutics
Hedge funds have recently modified their holdings of the stock. Simplify Asset Management Inc. boosted its position in shares of Akero Therapeutics by 15.6% in the third quarter. Simplify Asset Management Inc. now owns 283,766 shares of the company's stock worth $8,141,000 after acquiring an additional 38,279 shares during the last quarter. abrdn plc raised its holdings in Akero Therapeutics by 118.7% in the fourth quarter. abrdn plc now owns 269,782 shares of the company's stock valued at $7,505,000 after buying an additional 146,424 shares during the period. FMR LLC raised its holdings in Akero Therapeutics by 732.1% in the third quarter. FMR LLC now owns 30,337 shares of the company's stock valued at $870,000 after buying an additional 26,691 shares during the period. SG Americas Securities LLC raised its holdings in Akero Therapeutics by 4,022.1% in the fourth quarter. SG Americas Securities LLC now owns 597,993 shares of the company's stock valued at $16,636,000 after buying an additional 583,486 shares during the period. Finally, Barclays PLC raised its holdings in Akero Therapeutics by 127.9% in the third quarter. Barclays PLC now owns 127,668 shares of the company's stock valued at $3,662,000 after buying an additional 71,652 shares during the period.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on AKRO shares. UBS Group raised their target price on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a report on Friday, January 31st. Citigroup raised their target price on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Canaccord Genuity Group raised their target price on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. HC Wainwright raised their price target on shares of Akero Therapeutics from $50.00 to $72.00 and gave the stock a "buy" rating in a research note on Monday, January 27th. Finally, Bank of America raised shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and raised their price target for the stock from $35.00 to $63.00 in a research note on Thursday, January 30th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Akero Therapeutics currently has an average rating of "Buy" and a consensus price target of $75.86.
View Our Latest Stock Analysis on AKRO
Akero Therapeutics Company Profile
(
Get Free Report)
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
